SBFM Profile
Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company specializing in the research and development of innovative treatments for cancer and viral infections. The company’s primary focus is on the development of novel anticancer drugs, including its lead candidate Adva-27a. This drug is a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to target a broad spectrum of cancers, including leukemia, lymphoma, and solid tumors such as lung, prostate, and ovarian cancers. Adva-27a is particularly notable for its potential efficacy against multidrug-resistant cancer cells, including those in pancreatic, breast, and small-cell lung cancers.
In addition to its work on Adva-27a, Sunshine Biopharma is developing SBFM-PL4, a promising anti-coronavirus compound. This drug is aimed at addressing the urgent need for effective treatments against viral infections, potentially contributing to the global fight against emerging and existing coronaviruses. The company has secured a licensing agreement with the University of Georgia to advance the development of SBFM-PL4, leveraging academic research to enhance the drug’s efficacy and accelerate its path to market.
Beyond its pharmaceutical initiatives, Sunshine Biopharma also markets a range of nutritional supplements. These include Essential 9, a comprehensive multivitamin tablet, and Essential Calcium-Vitamin D, which supports bone health. The company is committed to developing science-based nutritional products that complement its therapeutic drug portfolio and meet the needs of health-conscious consumers.
Founded in 2006 and headquartered in Pointe-Claire, Canada, Sunshine Biopharma continues to build its presence in the biotechnology sector through strategic research, development partnerships, and innovative product offerings. The company's focus on both cutting-edge therapeutic solutions and high-quality nutritional supplements positions it as a versatile player in the health and wellness industry, dedicated to improving patient outcomes and advancing scientific knowledge.
|
